Contraline secures $92.5M Series B to fund Phase 3 trial of male contraceptive gel

Contraline, a startup developing a male contraceptive, announced it has closed a Series B financing round worth $92.5 million.

The capital will be used to advance its candidate, referred to as NES/T, into a Phase 3 clinical trial. The product is a daily gel applied to the shoulders.

The funding underscores growing investor interest in non-hormonal male birth control solutions and could accelerate the timeline for bringing the therapy to market.